CIA
SYRS

Capital Impact Advisors’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Capital Impact Advisors’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-16,860
Closed -$1.83M – 139
2020
Q4 		$1.83M Hold
16,860
– – 0.45% 87
2020
Q3 		$1.49M Buy
+16,860
New +$1.92M 0.44% 91

Other funds holding SYRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Capital Impact Advisors's SYRS Position: Q1 2021 in Review

Capital Impact Advisors sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2021, closing a stake of 16,860 shares — an estimated $1.83M sold.

Capital Impact Advisors first reported a position in SYRS in Q3 2020 and held it in 2 quarters. The position peaked at $1.83M in Q4 2020. 106 funds tracked by Wall St. Rank hold SYRS as of Q1 2021.

  • Capital Impact Advisors reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Capital Impact Advisors sold 16,860 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2021, an estimated $1.83M.
  • Capital Impact Advisors first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2020 and held it in 2 quarters.
  • Capital Impact Advisors's Syros Pharmaceuticals, Inc. Common Stock position peaked at $1.83M in Q4 2020.
  • 106 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2021.

Based on Capital Impact Advisors's 13F filing for Q1 2021, filed 18 May 2021.